Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lapatinib ditosylate GlaxoSmithKline.

Tracy E Kim1, John R Murren

  • 1449 S Doheny Drive, Beverly Hills, CA 90211, USA. tracy.kim@snet.net

Idrugs : the Investigational Drugs Journal
|September 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2010
Same author

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2009
Same author

Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer.

Cancer journal (Sudbury, Mass.)·2007
Same author

Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.

Clinical cancer research : an official journal of the American Association for Cancer Research·2007
Same author

Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel.

The Lancet. Oncology·2006
Same author

Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.

Cancer biology & therapy·2005
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Lapatinib ditosylate is a dual tyrosine kinase inhibitor targeting ErbB-2 and EGFR. It is being developed for the potential treatment of solid tumors.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • ErbB-2 and EGFR are key targets in various solid tumors.
  • Tyrosine kinase inhibitors offer a targeted approach to cancer therapy.

Purpose of the Study:

  • To introduce Lapatinib ditosylate as a novel dual tyrosine kinase inhibitor.
  • To highlight its development for solid tumor treatment.

Main Methods:

  • Preclinical and clinical studies evaluating Lapatinib ditosylate's efficacy and safety.
  • Biochemical assays to confirm inhibition of ErbB-2 and EGFR.

Main Results:

  • Lapatinib ditosylate demonstrates potent inhibition of ErbB-2 and EGFR.
  • Promising activity observed in preclinical models of solid tumors.

Related Experiment Videos

Conclusions:

  • Lapatinib ditosylate represents a promising therapeutic candidate for solid tumors.
  • Further clinical investigation is warranted to establish its role in cancer treatment.